TriSalus Life Sciences Inc (TLSI) has a current Price-to-Book (P/B) ratio of -11.39. Compared to its 3-year average P/B ratio of -4.20, the current P/B ratio is approximately 170.86% higher. Relative to its 5-year average P/B ratio of -2.81, the current P/B ratio is about 304.64% higher. TriSalus Life Sciences Inc (TLSI) has a Forward Free Cash Flow (FCF) yield of approximately -7.27%. Compared to its 3-year average FCF yield of -25.42%, the current FCF yield is approximately -71.40% lower. Relative to its 5-year average FCF yield of -18.04%, the current FCF yield is about -59.68% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TLSI competitors is 7.80, providing a benchmark for relative valuation. TriSalus Life Sciences Inc Corp (TLSI.O) exhibits a P/S ratio of 5.08, which is -34.87% above the industry average. Given its robust revenue growth of 59.79%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TLSI increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TLSI in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TLSI currently overvalued or undervalued?

What is TriSalus Life Sciences Inc (TLSI) fair value?

TLSI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of TriSalus Life Sciences Inc (TLSI) is between 4.28 to 5.57 according to relative valuation method.

How does TLSI's valuation metrics compare to the industry average?

The average P/S ratio for TLSI's competitors is 7.80, providing a benchmark for relative valuation. TriSalus Life Sciences Inc Corp (TLSI) exhibits a P/S ratio of 5.08, which is -34.87% above the industry average. Given its robust revenue growth of 59.79%, this premium appears sustainable.

What is the current P/B ratio for TriSalus Life Sciences Inc (TLSI) as of Mar 02 2026?

As of Mar 02 2026, TriSalus Life Sciences Inc (TLSI) has a P/B ratio of -11.39. This indicates that the market values TLSI at -11.39 times its book value.

What is the current FCF Yield for TriSalus Life Sciences Inc (TLSI) as of Mar 02 2026?

As of Mar 02 2026, TriSalus Life Sciences Inc (TLSI) has a FCF Yield of -7.27%. This means that for every dollar of TriSalus Life Sciences Inc's market capitalization, the company generates -7.27 cents in free cash flow.

What is the current Forward P/E ratio for TriSalus Life Sciences Inc (TLSI) as of Mar 02 2026?

As of Mar 02 2026, TriSalus Life Sciences Inc (TLSI) has a Forward P/E ratio of -23.51. This means the market is willing to pay $-23.51 for every dollar of TriSalus Life Sciences Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for TriSalus Life Sciences Inc (TLSI) as of Mar 02 2026?

As of Mar 02 2026, TriSalus Life Sciences Inc (TLSI) has a Forward P/S ratio of 5.08. This means the market is valuing TLSI at $5.08 for every dollar of expected revenue over the next 12 months.

TLSI Valuation